Sugi Predict

Sugi Predict / Targets / FLT4

FLT4

Vascular endothelial growth factor receptor 3 · P35916 · FLT4 on Sugi Atlas →

168,155 patent compounds predicted against FLT4, 121,413 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vandetanib Vandetanib (SCHEMBL9044) 1.00 11/20
Linifanib Linifanib (SCHEMBL93804) 1.00 10/20
SCHEMBL90887 SCHEMBL90887 0.49 7/20
SCHEMBL90935 SCHEMBL90935 0.49 7/20
SCHEMBL60289 SCHEMBL60289 0.48 7/20
SCHEMBL58735 SCHEMBL58735 0.47 7/20
SCHEMBL11517 SCHEMBL11517 0.84 6/20
SCHEMBL9280 SCHEMBL9280 0.64 6/20
SCHEMBL58313 SCHEMBL58313 0.59 6/20
SCHEMBL58543 SCHEMBL58543 0.57 6/20
SCHEMBL60464 SCHEMBL60464 0.57 6/20
SCHEMBL59547 SCHEMBL59547 0.49 6/20
SCHEMBL66159 SCHEMBL66159 0.49 6/20
SCHEMBL60366 SCHEMBL60366 0.47 6/20
SCHEMBL58496 SCHEMBL58496 0.44 6/20
Cediranib Cediranib (SCHEMBL63147) 1.00 5/20
SCHEMBL57890 SCHEMBL57890 0.53 5/20
SCHEMBL39499 SCHEMBL39499 0.51 5/20
SCHEMBL58732 SCHEMBL58732 0.51 5/20
SCHEMBL58416 SCHEMBL58416 0.50 5/20

Clinical trials — most relevant to FLT4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma PHASE3COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites PHASE1/PHASE2RECRUITING
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma PHASE2COMPLETED
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma PHASE2COMPLETED
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers PHASE1/PHASE2COMPLETED
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma PHASE2ACTIVE_NOT_RECRUITING
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients PHASE2UNKNOWN
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment PHASE2COMPLETED
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) PHASE1COMPLETED
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration PHASE1COMPLETED
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function PHASE1COMPLETED
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial nanUNKNOWN
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis nanUNKNOWN
Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia nanCOMPLETED
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler nanNOT_YET_RECRUITING
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece nanCOMPLETED
Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FLT4 binder may also engage these)

ProteinNameSimilarity
P35917 — 1.000 P35917 →
Q91ZT1 — 1.000 Q91ZT1 →
P79701 — 0.994 P79701 →
Q00495 — 0.993 Q00495 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.992 landscape →
P35969 — 0.992 P35969 →
P53767 — 0.992 P53767 →
P52583 — 0.992 P52583 →
Q8QHL3 — 0.992 Q8QHL3 →
Q5GIT4 — 0.991 Q5GIT4 →
KDR Vascular endothelial growth factor receptor 2 0.991 landscape →
P35546 — 0.991 P35546 →
P13369 — 0.990 P13369 →
Q8K1S3 — 0.990 Q8K1S3 →
Q6QNF3 — 0.990 Q6QNF3 →
FLT1 Vascular endothelial growth factor receptor 1 0.990 landscape →
Q92729 — 0.990 Q92729 →
P09581 — 0.989 P09581 →
PDGFRB Platelet-derived growth factor receptor beta 0.989 landscape →
Q5MD89 — 0.989 Q5MD89 →
B6ZK77 — 0.989 B6ZK77 →
B4HY03 — 0.989 B4HY03 →
Q8AXC7 — 0.988 Q8AXC7 →
P00545 — 0.988 P00545 →
P60029 — 0.987 P60029 →
A6NFU0 — 0.987 A6NFU0 →
D3YX43 — 0.987 D3YX43 →
Q8JFR5 — 0.987 Q8JFR5 →
Q96PQ0 — 0.987 Q96PQ0 →
O08721 — 0.986 O08721 →